George Kelly: Okay. That’s helpful. And then next topic I wanted to cover is — relates to your guidance and commentary about your sort of one half versus two half expectations on procedure revenue growth. I’m curious, the 6.6% growth now that you’ve reported for two consecutive quarters, do you think that’s the bottom? And then as you look to the acceleration that you’ve talked to in the back half, is that mostly driven by new products? Or is it really just the core business kind of starting to find its momentum again and new products are more of a ’25 and beyond kind of story?
Terry Weber: I think we can kind of answer that multiple ways, George. So definitely, that Q1 performance was consistent with our expectations, and we feel as if we understand our providers and we understand the competitive market. And I feel that we are very confident in where those procedure revenue growth is going to come from in Q2 as well as Q3 and 4. So although we point you to Q3 and 4, and we’ve got solid plans in place and really looking at that formulas, very comfortable with them for that Q3 and Q4. And I’ll have Bob talk a little bit about some of the individual programs.
Bob Peterson: Yes, sure. And George, good question. And we factored the following kind of piece parts into our guidance. I would say that the two big pieces, one is on the procedure side. And I’ll just hit the high points and then I can dive into any of them in more depth. But you heard from Terry, you heard from me earlier, the heightened focus on our top tier growth is absolutely mission critical for us. We are seeing these performing well, and we expect to have that play through in the second half. Additionally, as I just mentioned, and I won’t go into this too much because I’ve already commented, but we need to be growing new customers. And we’ve seen with the Quick Starts and the other items that we’ve mentioned pretty solid uptick there.
One that I think is though, we didn’t dive into too much but it’s how do we drive those existing customers that may be newer or in the middle of their journey, of their life cycle with us, how do we start to drive them, leveraging our sales force and internal data to drive opportunities to really expand within our portfolio. And I think that’s a real key for us because there are more people we can get into our top tiers, the better we will perform. And Terry mentioned it earlier, and I would just echo it. The — we do have a really great sales force that’s really battle tested in this area, and I think that’s key to mention. And the only other side of the equation that I would bring up is as we look at nutras, we need to continue to expand nutras into our existing customer base, continue to make good penetration, especially in those newer customers and even some of the older customers that may not be acclimated to nutras.
And that’s a real focus of our sales force, and we are seeing good uptake there. And then finally, as you know and we’ve talked about on the prior call is that conversion from Amazon — from our prior distributor and seeing that growth because that should — if we can get that up and running, which we are on pace to do in the second half, that will be very accretive.
George Kelly: Okay. That was a hopeful info. Thank you.
Bob Peterson: Thank you.
Operator: With that question, [technical difficulty]. I would like to turn the conference over back for any closing remarks.
Terry Weber: I’d like to say thank you to all of you for joining us. We look forward to updating you as the year goes on, on our therapeutic wellness and the real positive impact we are seeing on hormone optimization and the interest throughout the U.S. So looking forward to our next call. Thank you.
Bob Peterson: Thank you.
